comparemela.com

Latest Breaking News On - Protagonist therapeutics inc - Page 1 : comparemela.com

Insider Selling: Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Director Sells 8,000 Shares of Stock

Protagonist Therapeutics, Inc. (NASDAQ:PTGX – Get Free Report) Director William D. Waddill sold 8,000 shares of the firm’s stock in a transaction dated Friday, June 7th. The shares were sold at an average price of $35.00, for a total transaction of $280,000.00. Following the completion of the transaction, the director now directly owns 12,000 shares […]

Florida
United-states
Zurcher-kantonalbank-zurich-cantonalbank
Williamd-waddill
Principal-financial-group-inc
Nasdaq
Protagonist-therapeutics-inc
Board-of-administration-florida-retirement-system
Hennion-walsh-asset-management-inc
Proshare-advisors
Jpmorgan-chase-co
Protagonist-therapeutics

Protagonist Therapeutics to Participate in the Jefferies Global Healthcare ...

Protagonist Therapeutics to Participate in the Jefferies Global Healthcare ...
pr-inside.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from pr-inside.com Daily Mail and Mail on Sunday newspapers.

Corey-davis
Dineshv-patel
Protagonist-therapeutics-inc
Johnson
Network-of-companies
News-network
Protagonist-therapeutics
Chief-executive-officer
Jefferies-global-healthcare-conference
New-york-city
Global-healthcare-conference
Johnson-innovative-medicine

Protagonist Therapeutics to Participate in the Jefferies Global Healthcare Conference 2024

Protagonist Therapeutics to Participate in the Jefferies Global Healthcare Conference 2024
tennesseedaily.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tennesseedaily.com Daily Mail and Mail on Sunday newspapers.

Dineshv-patel
Corey-davis
Network-of-companies
Johnson
Protagonist-therapeutics-inc
Protagonist-therapeutics
Chief-executive-officer
Jefferies-global-healthcare-conference
New-york-city
Johnson-innovative-medicine
New-england-journal

Protagonist Therapeutics Announces Oral Presentation on Long-Term Follow-up of Rusfertide Phase 2 RE

NEWARK, CA / ACCESSWIRE / May 14, 2024 / Protagonist Therapeutics, Inc. (NASDAQ:PTGX) ("Protagonist" or the "Company") today announced that additional data from the rusfertide Phase 2 REVIVE open label extension study will be the focus of an oral presentation at the European Hematology Associatio.

Ann-arbor
Michigan
United-states
Spain
Madrid
Hall-goya
Kristenm-pettit
Corey-davis
Division-of-hematology-oncology
Department-of-internal-medicine
Network-of-companies
University-of-michigan

vimarsana © 2020. All Rights Reserved.